🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07245329
Recruiting Not applicable

Effect of Full-House ESS With Nasopharyngeal Lymphoid Tissue Ablation on Nasal Polyps

NCT07245329 · tracked via the Priya Life Science China tracker
Sponsor
Tongji Hospital
Phase
Not applicable
Started
2025-07-01
Last updated
2025-11-24

Condition(s) studied

Nasal Polyps

Investigational drug(s) / intervention(s)

Nasopharyngeal Lymphoid Tissue AblationFull-House Endoscopic Sinus Surgery

Nasopharyngeal Lymphoid Tissue Ablation: The nasal mucosa is initially decongested using a topical vasoconstrictor. A small-caliber urethral catheter is then introduced through each nasal cavity to elevate the soft palate. A 45° rigid nasoendoscope is inserted transorally to visualize the nasopharynx. Under endoscopic guidance, the nasopharyngeal lymphoid tissue is identified on the nasopharyngeal roof. Following aspiration of any secretions, the tissue is completely resected with a plasma scalpel.

Full-House Endoscopic Sinus Surgery: After complete removal of the nasal polyps, a full ethmoidectomy is performed, removing all bony septa within the sinuses. Conventional sphenoidotomy and frontal sinusotomy are carried out, with or without preservation of the middle turbinate. Only irreversibly polypoid mucosa is resected, while normal mucosa is preserved.

Study summary

This study is designed to evaluate whether the addition of nasopharyngeal lymphoid tissue ablation to full-house endoscopic sinus surgery (ESS) provides superior control of nasal mucosa inflammation compared to full-house ESS alone in patients with nasal polyps. Thirty-two adult participants will be randomly assigned to undergo either full-house ESS only or full-house ESS combined with nasopharyngeal lymphoid tissue ablation. The primary outcome will be assessed through changes in inflammatory cell profiles at 1, 3, and 6 months postoperatively. Secondary outcomes include inflammatory cytokine levels, symptom scores, endoscopic findings, polyp recurrence rates, and safety measures.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Aged 18-65 years * Diagnosed with CRSwNP according to EPOS criteria * Blood eosinophil count \> 0.3 × 10⁹/L Exclusion Criteria: * Pregnant or lactating women. * Cystic fibrosis * primary ciliary dyskinesia * fungal ball rhinosinusitis * systemic vasculitis or granulomatous disease * malignancy * immunodeficiency. * Subjects with an upper-respiratory-tract infection within the past 4 weeks. * Clinically significant metabolic, cardiovascular, immune, neurologic, hematologic, gastrointestinal, cerebrovascular, or respiratory disorders, or any condition that, in the investigator's opinion, could interfere with outcome assessment or compromise patient safety. * Currently participating in another clinical trial or having participated in one within 30 days, or staff directly involved in this study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology Wuhan Hubei Recruiting

More Tongji Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07245329 on ClinicalTrials.gov ↗ ← All trials in China